A simple mathematical model based on the cancer stem cell hypothesis suggests kinetic commonalities in solid tumor growth

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Molina Peña, Rodolfo ^a   Álvarez, Mario Moisés ^a  

^a SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL KILLING; CELL KINETICS; CELL PROLIFERATION; CELL RENEWAL; CELL SUBPOPULATION; CHEMICAL REACTION; CONTROLLED STUDY; DRUG TARGETING; FEASIBILITY STUDY; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; SOLID TUMOR; VALIDATION PROCESS; BIOLOGICAL MODEL; DATA BASE; DISEASE COURSE; HUMAN; KINETICS; NEOPLASM; PATHOLOGY; STATISTICAL MODEL;

CELL DEATH; CELL PROLIFERATION; DATABASES AS TOPIC; DISEASE PROGRESSION; HUMANS; KINETICS; LINEAR MODELS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84857171440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026233     Document Type: Article

References (91)

1. Mertens PPC, Maan S, Samuel A, Attoui H, (2005) Virus Taxonomy VIIIth Report of the ICTV Elsevier/Academic Press London pp. 466-483.
2. OIE (2006) Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. 6th ed. Paris.
3. Roy P, (2008) Functional mapping of bluetongue virus proteins and their interactions with host proteins during virus replication. Cell Biochem Biophys 50: 143-157.
4. Roy P, (2005) Bluetongue virus proteins and particles and their role in virus entry, assembly, and release. Adv Virus Res 64: 69-123.
5. Maan S, Maan NS, Ross-smith N, Batten CA, Shaw AE, et al. (2008) Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains. Virology 377: 308-318.
6. ISID Promed mail (2006) Bluetongue- Europe (1): Bluetongue, ovine, Netherlands, confirmed: ProMED-mail 2006; 18 Aug: 20060818.2311. http://www.promedmail.org.
7. ISID Promed mail (2008) Bluetongue- EUROPE (69): Netherlands, BTV-6 Vaccine strain update: ProMED-mail 2008; 31 Oct: 20081031.3431. http://www.promedmail.org.
8. Eschbaumer M, Hoffmann B, Moss A, Savini G, Leone A, et al. (2009) Emergence of bluetongue virus serotype 6 in Europe-German field data and experimental infection of cattle. Vet Microbiol 143: 189-195.
9. De Clercq K, Mertens P, De Leeuw I, Oura C, Houdart P, et al. (2009) Emergence of bluetongue serotypes in Europe, part 2: the occurrence of a BTV-11 strain in Belgium. Transbound Emerg Dis 56: 355-361.
10. Maan S, Maan NS, van Rijn PA, van Gennip RG, Sanders A, et al. (2010) Full genome characterisation of bluetongue virus serotype 6 from the Netherlands 2008 and comparison to other field and vaccine strains. PLoS One 5: e10323.
11. Hofmann MA, Renzullo S, Mader M, Chaignat V, Worwa G, et al. (2008) Genetic characterization of toggenburg orbivirus, a new bluetongue virus, from goats, Switzerland. Emerg Infect Dis 14: 1855-1861.
12. Meiswinkel R, van Rijn P, Leijs P, Goffredo M, (2007) Potential new Culicoides vector of bluetongue virus in northern Europe. The Veterinary record 161: 564-565.
13. Dijkstra E, van der Ven IJ, Meiswinkel R, Holzel DR, Van Rijn PA, et al. (2008) Culicoides chiopterus as a potential vector of bluetongue virus in Europe. Vet Rec 162: 422.
14. Mehlhorn H, Walldorf V, Klimpel S, Jahn B, Jaeger F, et al. (2007) First occurrence of Culicoides obsoletus-transmitted Bluetongue virus epidemic in Central Europe. Parasitol Res 101: 219-228.
15. Backx A, Heutink R, van Rooij E, van Rijn P, (2009) Transplacental and oral transmission of wild-type bluetongue virus serotype 8 in cattle after experimental infection. Vet Microbiol 138: 235-243.
16. EFSA, (2011) EFSA Panel on Animal Health and Welfare (AHAW); Scientific Opinion on bluetongue serotype 8. EFSA Journal 9 (5): 5175 [51 pp 9: 51.
17. Gao JX, (2008) Cancer stem cells: the lessons from pre-cancerous stem cells. J Cell Mol Med 12: 67-96.
18. Hermann PC, Huber SL, Heeschen C, (2008) Metastatic cancer stem cells: a new target for anti-cancer therapy? Cell cycle 7: 188-193.
19. Jagani Z, Khosravi-Far R, (2008) Cancer stem cells and impaired apoptosis. Adv Exp Med Biol 615: 331-344.
20. Kai K, Nagano O, Sugihara E, Arima Y, Sampetrean O, et al. (2009) Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Sci 100: 2275-2282.
21. Schmidt C, (2008) Drug makers chase cancer stem cells. Nat Biotechnol 26: 366-367.
22. Cho RW, Clarke MF, (2008) Recent advances in cancer stem cells. Curr Opin Genet Dev 18: 48-53.
23. Clarke MF, Fuller M, (2006) Stem cells and cancer: two faces of eve. Cell 124: 1111-1115.
24. Rapp UR, Ceteci F, Schreck R, (2008) Oncogene-induced plasticity and cancer stem cells. Cell Cycle 7: 45-51.
25. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
26. Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE, (1997) Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A 94: 5320-5325.
27. Gudjonsson T, Magnusson MK, (2005) Stem cell biology and the cellular pathways of carcinogenesis. APMIS 113: 922-929.
28. Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, et al. (2008) Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res 314: 2110-2122.
29. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
30. Vermeulen L, Todaro M, De Sousa F, Sprick MR, Kemper K, et al. (2008) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 105: 13427-13432.
31. Ailles LE, Weissman IL, (2007) Cancer Stem cells in solid tumors. Curr Opin Biotechnol 18: 460-466.
32. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
33. Loebinger MR, Giangreco A, Groot KR, Prichard L, Allen K, et al. (2008) Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br J Cancer 98: 380-387.
34. Kang MK, Hur BI, Ko MH, Kim CH, Cha SH, et al. (2008) Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma. BMC Neurosci 9: 15.
35. Friel AM, Sergent PA, Patnaude C, Szotek PP, Oliva E, et al. (2008) Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell cycle 7: 242-249.
36. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
37. Collins AT, Maitland NJ, (2008) Prostate cancer stem cells. Eur J Cancer 42: 1213-1218.
38. Maitland NJ, Collins AT, (2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26: 2862-2870.
39. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, et al. (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE 3: e2428.
40. Pan Y, Huang X, (2008) Epithelial ovarian cancer stem cells- a review. Int J Clin Exp Med 1: 260-266.
41. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567.
42. Eyler CE, Rich JN, (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26: 2839-2845.
43. Los M, (2009) New, exciting developments in experimental therapies in the early 21st century. Eur J Pharmacol 625: 1-5.
44. Saini V, Shoemaker RH, (2010) Potential for therapeutic targeting of tumor stem cells. Cancer Sci 101: 16-21.
45. Scatena R, Bottoni P, Pontoglio A, Giardina B, (2011) Cancer stem cells: the development of new cancer therapeutics. Expert Opinion on Biological Therapy 11 (7): 875-892.
46. Michor F, (2008) Mathematical models of cancer stem cells. J Clin Oncol 26: 2854-2861.
47. Boman BM, Wicha MS, Fields JZ, Runquist OA, (2007) Symmetric division of cancer stem cells-a key mechanism in tumor growth that should be targeted in future therapeutic approaches. Clin Pharmacol Ther 81: 893-898.
48. Daukste L, Basse B, Baguley BC, Wall DJN, (2009) Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them. J Theor Biol 260: 563-571.
49. Dingli D, Traulsen A, Michor F, (2007) (A)symmetric stem cell replication and cancer. PLoS Comput Biol 3: e53.
50. Dingli D, Traulsen A, Pacheco JM, (2007) Compartmental Architecture and Dynamics of Hematopoiesis. PLoS ONE 2: e345.
51. Dingli D, Traulsen A, Pacheco JM, (2007) Stochastic dynamics of hematopoietic tumor stem cells. Cell Cycle 6: 461-466.
52. Dingli D, Michor F, (2006) Successful therapy must eradicate cancer stem cells. Stem Cells 24: 2603-2610.
53. Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F, (2009) Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 5: e1000503.
54. Galle J, Hoffmann M, Aust G, (2009) From single cells to tissue architecture-a bottom-up approach to modelling the spatio-temporal organisation of complex multi-cellular systems. J Math Biol 58: 261-283.
55. Ganguly R, Puri IK, (2007) Mathematical model for chemotherapeutic drug efficacy in arresting tumour growth based on the cancer stem cell hypothesis. Cell Prolif 40: 338-354.
56. Johnston MD, Edwards CM, Bodmer WF, Maini PK, Chapman SJ, (2007) Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer. Proc Natl Acad Sci U S A 104: 4008-4013.
57. Kim PS, Lee PP, Levy D, (2008) A PDE model for imatinib-treated chronic myelogenous leukemia. Bull Math Biol 70: 1994-2016.
58. Komarova NL, Wodarz D, (2007) Effect of Cellular Quiescence on the Success of Targeted CML Therapy. PLoS ONE 2: e990.
59. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, et al. (2005) Dynamics of chronic myeloid leukaemia. Nature 435: 1267-1270.
60. Pacheco JM, Traulsen A, Dingli D, (2009) The allometry of chronic myeloid leukemia. J Theor Biol 259: 635-640.
61. T urner C, Stinchcombe AR, Kohandel M, Singh S, Sivaloganathan S, (2009) Characterization of brain cancer stem cells: A mathematical approach. Cell Prolif 42: 529-540.
62. Bonnet D, Dick JE, (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
63. Dick JE, (2008) Stem cell concepts renew cancer research. Blood 112: 4793-4807.
64. Bapat SA, Mali AM, Koppikar CB, Kurrey NK, (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029.
65. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG, (2008) PC-3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 68: 1820-1825.
66. Pfeiffer MJ, Schalken JA, (2010) Stem Cell Characteristics in Prostate Cancer Cell Lines. Eur Urol 57: 246-255.
67. Tan L, Sui X, Deng H, Ding M, (2011) Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells. PLos One 6 (8): e23383.
68. Morrison SJ, Kimble J, (2006) Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 441: 1068-1074.
69. Soltysova A, Altanerova V, Altaner C, (2005) Cancer stem cells. Neoplasma 52: 435-440.
70. Caussinus E, Hirth F, (2007) Asymmetric stem cell division in development and cancer. Prog Mol Subcell Biol 45: 205-25.
71. Giebel B, Bruns I, (2008) Self-renewal versus differentiation in hematopoietic stem and progenitor cells: a focus on asymmetric cell divisions. Curr Stem Cell Res Ther 3: 9-16.
72. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, et al. (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 103: 1480-1485.
73. Cocciadiferro L, Miceli V, Kang KS, Polito LM, Trosko JE, et al. (2009) Profiling Cancer Stem Cells in Androgen-Responsive and Refractory Human Prostate Tumor Cell Lines. Ann N Y Acad Sci 1155: 257-262.
74. Morrison SJ, Shah NM, Anderson DJ, (1997) Regulatory mechanisms in stem cell biology. Cell 88: 287-298.
75. Ashkenazi R, Gentry SN, Jackson TL, (2008) Pathways to Tumorigenesis-modeling mutation acquisition in stem cells and their progeny. Neoplasia 10: 1170-1182.
76. Mackenzie IC, (2008) Cancer stem cells. Ann Oncol 19: v40-v43.
77. Maitland NJ, Bryce SD, Stower MJ, Collins AT, (2007) Prostate cancer stem cells: a target for new therapies. Ernst Schering Found Symp Proc 5: 155-179.
78. Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, et al. (2004) Molecular cell biology, 5th edn New York W. H. Freeman & Co.
79. Roose T, Chapman SJ, Maini PK, (2007) Mathematical models of avascular tumor growth. SIAM Review 49: 179-208.
80. Senoo M, Pinto F, Crum C, McKeon F, (2008) p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129: 523-536.
81. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF, (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14: 43-47.
82. Lobo NA, Shimono Y, Qian D, Clarke MF, (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23: 675-699.
83. Yanamoto S, Kawasaki G, Yamada S-i, Yoshitomi I, Kawano T, et al. (2011) Isolation and characterization of cancer stem-like side population cells in human oral cancer cells. Oral oncology (in press).
84. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708.
85. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, et al. (1996) Characterization of a novel androgen-sensitive prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 2: 1039-1048.
86. Winquist RJ, Boucher DM, Wood M, Furey BF, (2009) Targeting cancer stem cells for more effective therapies: taking out cancer's locomotive engine. Biochem Pharmacol 78: 326-334.
87. Ji Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 4: e6816.
88. Sagar J, Chaib B, Sales K, Winslet M, Seifalian A, (2007) Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell International 7: 9-11.
89. Kern SE, Shibata D, (2007) The fuzzy math of solid tumor stem cells: a prespective. Cancer Research 67: 8985-8988.
90. Sell S, (2004) Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51: 1-28.
91. Sell S, (2005) Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev 1: 197-205.